Jonathan Barret United KingdomUniversity of Leicester, Leicester, UK

My research is focussed on a bench to bedside approach to improving our understanding of the pathogenesis of IgA nephropathy a common global cause of kidney failure. I am the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and Convener of the International IgA Nephropathy Network. I work closely with pharmaceutical companies interested in new treatments for IgA nephropathy, and am Chief Investigator for a number of international randomised controlled Phase 2 and 3 clinical trials in IgA nephropathy. I was a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Work group. I am an Editorial Board member for Kidney International and the American Society of Nephrology journals. I am a co-Chair of the UK Glomerulonephritis Clinical Study Group and am the IgA nephropathy lead for the KDIGO Clinical Practice Guidelines for Glomerular Diseases.